Raymond James raised the firm’s price target on Johnson & Johnson to $164 from $162 and keeps an Outperform rating on the shares. The firm notes Q1 results generated revenue/EPS upside. Pharma was the highlight, offset by weaker MedTech and gross margins. Considering the 470bp of LOE headwind tied to Stelara, low single-digit growth is respectable, Raymond adds. The new guidance seems beatable, but the impact of Pharma tariffs remains a risk, says the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $169 from $164 at Morgan Stanley
- Johnson & Johnson price target raised to $161 from $159 at BofA
- Johnson & Johnson price target raised to $159 from $158 at Bernstein
- Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges
- Johnson & Johnson: Balancing Stability and Risks Amid Tariff Challenges